Bicocca Open Archive

Logo unimib boa
MOLOGNI, LUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.329
EU - Europa 4.475
AS - Asia 1.889
SA - Sud America 33
Continente sconosciuto - Info sul continente non disponibili 15
AF - Africa 13
OC - Oceania 8
Totale 14.762
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.203
IT - Italia 1.237
DE - Germania 777
SG - Singapore 708
CN - Cina 684
IE - Irlanda 637
SE - Svezia 534
RU - Federazione Russa 365
UA - Ucraina 268
GB - Regno Unito 201
HK - Hong Kong 195
CA - Canada 125
FI - Finlandia 104
FR - Francia 92
ID - Indonesia 85
IN - India 77
PL - Polonia 73
BE - Belgio 60
VN - Vietnam 47
TR - Turchia 43
DK - Danimarca 36
NL - Olanda 28
BR - Brasile 20
IR - Iran 15
EU - Europa 14
ES - Italia 13
JP - Giappone 10
KR - Corea 10
AU - Australia 8
PE - Perù 8
LT - Lituania 7
CZ - Repubblica Ceca 6
EG - Egitto 5
RO - Romania 5
AT - Austria 4
BG - Bulgaria 4
CL - Cile 4
MK - Macedonia 4
NO - Norvegia 4
CH - Svizzera 3
MY - Malesia 3
BY - Bielorussia 2
GR - Grecia 2
MU - Mauritius 2
PT - Portogallo 2
SC - Seychelles 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BD - Bangladesh 1
EE - Estonia 1
KE - Kenya 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MA - Marocco 1
MD - Moldavia 1
NG - Nigeria 1
PK - Pakistan 1
PR - Porto Rico 1
PS - Palestinian Territory 1
RS - Serbia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TW - Taiwan 1
YE - Yemen 1
Totale 14.762
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.939
Woodbridge 726
Fairfield 689
Dublin 627
Chandler 602
Frankfurt am Main 593
Singapore 571
Milan 488
Wilmington 444
Houston 410
Ashburn 381
Jacksonville 267
Seattle 253
Cambridge 247
Dearborn 247
New York 238
Santa Clara 198
Hong Kong 194
Princeton 172
Nanjing 124
Shanghai 121
Jakarta 85
Altamura 83
Lawrence 79
Beijing 71
Lodz 70
Brussels 56
Helsinki 53
San Diego 47
Lachine 44
Boardman 41
Fremont 38
Guangzhou 36
Lissone 36
Shenyang 34
Munich 32
Nanchang 32
Andover 31
Los Angeles 30
Ottawa 29
Romola 29
Toronto 29
Göttingen 27
Rome 26
Jinan 22
Carate Brianza 21
Falls Church 21
Jiaxing 21
Hebei 20
Kunming 20
London 19
Mountain View 19
Norwalk 19
Chicago 18
Kocaeli 17
Pune 17
Dong Ket 16
Edmonton 16
Hangzhou 16
Monza 16
Tianjin 16
Desio 14
Redmond 13
Turin 13
Changsha 12
Como 11
Kiev 11
Taizhou 11
Bari 10
Cesano Maderno 10
Genoa 10
Zhengzhou 10
Bonndorf 9
Cinisello Balsamo 9
Fürstenwalde 9
Paris 9
Sesto San Giovanni 9
Hefei 8
Washington 8
Changchun 7
Daejeon 7
Huizen 7
Lima 7
Mumbai 7
Riva del Garda 7
Boston 6
Detroit 6
Duncan 6
Kilburn 6
Lanzhou 6
Lleida 6
Meda 6
Ningbo 6
Phoenix 6
Corsico 5
Delhi 5
Lappeenranta 5
Modena 5
Moscow 5
Pavia 5
Totale 11.195
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 358
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 320
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 291
Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer 282
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency 275
Characterization of compound 584, an Abl kinase inhibitor with lasting effects 266
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 265
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 257
Three novel patients derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors 245
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma 226
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 222
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors 217
Immune Recognition of ALK Fusion Proteins in Patients with ALK-Rearranged Non-Small Cell Lung Cancer 210
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 208
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients 203
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 203
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling 200
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 198
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma 197
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 197
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 192
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy 190
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase 190
Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors 189
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 189
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 189
Inhibition of RET tyrosine kinase by SU5416 188
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036 187
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors 185
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells 181
Expression, purification, and inhibition of human RET tyrosine kinase 180
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors 179
Epigenetic Silencing of the Proapoptotic Gene BIM in Anaplastic Large Cell Lymphoma through an MeCP2/SIN3a Deacetylating Complex 178
Oncoscore, a Novel, Internet-Based Tool to Assess the Oncogenic Potential of Genes Can Differentiate Between CP-CML and BC-CML Associated Genes, and Between CP-CML Patients with Good and Bad Prognosis 175
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 174
We shall overcome (drug resistance) some day 171
Efficacy of a cancer vaccine against ALK-rearranged lung tumors 170
Dissection of the RET/ß-catenin interaction in the TPC1 thyroid cancer cell line 169
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation 166
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells 166
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells 165
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer 163
Dual kinase targeting in leukemia 163
Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK 159
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 157
Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications 156
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 156
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3- thienyl)nicotinonitrile scaffold 152
BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells 151
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism 148
Current and future treatment of anaplastic lymphoma kinase-rearranged cancer 145
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting 140
Novel targeted therapeutics for MEN2 140
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 140
Unique substrate specificity of Anaplastic Lymphoma Kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity 138
Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl 133
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 132
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2 131
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 128
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 127
Anaplastic Lymphoma kinase assay, reagents and composition thereof 121
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 120
Abstract 3583: Drug-resistant NPM/ALK mutants show different sensitivity to second generation tyrosine kinase inhibitors 119
New developments in the treatment of ALK-driven malignancies 118
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients 117
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 116
Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency 114
RET kinase inhibitors: a review of recent patents (2012–2015) 111
Synergistic Activity of ALK and mTOR Inhibitors for the Treatment of NPM-ALK Positive Lymphoma 110
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy 108
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 104
The novel PIM1 inhibitor NMS-P645 reverses PIM1-Dependent effects on TMPRSS2/ERG positive Prostate cancer cells and shows anti-proliferative activity in combination with PI3K inhibition 102
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 101
Targeted deletion of the muscular dystrophy gene myotilin does not perturb muscle structure or function in mice 100
Characterization of mouse myotilin and its promoter 100
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells 100
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma 98
Expanding the portfolio of anti-ALK weapons 97
Role of TMPRSS2/ERG in cellular transformation 94
Characterization of the transcriptional landscape of atypical Chronic Myeloid Leukemia at single-cell resolution 93
Targeting drug resistance mutations: Discovery of EUD-GK-91 chemical series 93
Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead 91
Erratum: Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma (Molecular Cancer Research (2015) 13 (775-783)) 90
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome 89
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 85
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 85
Mechanisms of resistance to the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma cells 84
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 84
Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 80
Synergistic activity of dasatinib in combination with β-catenin blockade in colorectal cancer cells 80
Balanced SET levels favor the correct enhancer repertoire during cell fate acquisition 79
Development of RET kinase inhibitors for targeted cancer therapy 77
Evolutionary signatures of human cancers revealed via genomic analysis of over 35,000 patients 76
Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo 74
Characterization of cancer subtypes associated with clinical outcomes by multi-omics integrative clustering 70
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 70
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1 67
Validation of a new NGS-based myeloid panel in acute myeloid leukemia: A single-center experience 65
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 61
Inhibitors of the anaplastic lymphoma kinase 57
Totale 15.072
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.235
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.235
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.518 0 0 0 0 0 286 396 208 237 171 159 61
2020/20212.141 93 107 204 252 168 208 179 214 187 204 151 174
2021/20221.316 112 154 136 70 54 102 80 72 62 119 147 208
2022/20232.642 289 734 209 237 176 353 28 138 180 134 85 79
2023/20242.204 113 87 98 113 255 562 400 68 177 57 55 219
2024/20251.971 275 476 319 278 440 183 0 0 0 0 0 0
Totale 15.423